

Datasheet: HCA387

Description:	HUMAN ANTI AFLIBERCEPT
Specificity:	AFLIBERCEPT
Other names:	Eylea, Zaltrap
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD38645ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Aflibercept

Specificity **Human Anti-Aflibercept Antibody, clone AbD38645ia** is a recombinant antibody that specifically recognizes the fusion protein drug aflibercept as well as the vascular endothelial growth factor receptor 1 (VEGFR1). It does not recognize vascular endothelial growth factor receptor 2 (VEGFR2). The antibody binds to free aflibercept and can be used to measure free aflibercept or aflibercept biosimilars in patient samples.

Clone AbD38645ia is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay.

Aflibercept (Eylea, Zaltrap) is a recombinant fusion protein consisting of the extra-cellular domain of human VEGF receptors 1 and 2, fused to the Fc portion of human IgG1. It is used to treat the 'wet' form of age-related macular degeneration (AMD) and impaired vision due to macular oedema. It is also used in the treatment of metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and irinotecan in patients previously treated with an oxaliplatin-containing chemotherapy. Aflibercept binds to circulating VEGF-A and VEGF-B to inhibit their ability to promote angiogenesis.

[View a summary of all anti aflibercept antibodies](#)

Affinity The intrinsic affinity of the monovalent form of Human anti Aflibercept antibody, clone AbD38645ia is $K_D = 1$ nM as measured by real time, label free molecular interaction analysis on immobilized Aflibercept

ELISA Human anti Aflibercept antibody, clone AbD38645ia can be used in an indirect ELISA. It can also be used as a calibrator in an anti-drug antibody assay.

Protocol: [ADA Bridging ELISA](#)

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Acknowledgements This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Eylea is a trademark of Regeneron/Sanofi.

Zaltrap is a trademark of Regeneron/Bayer Healthcare.

Health And Safety Information Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/HCA387>
10040

Licensed Use For *in vitro* research purposes and for commercial applications for the provision of *in vitro* testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

[HUMAN ANTI AFLIBERCEPT \(HCA386\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA388\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA389\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA390\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M432880:240913'

Printed on 13 Sep 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)